IPM Take
Alzheimer’s medicine is becoming increasingly quantitative. Amyloid burden is standardised, tau is mapped, blood biomarkers are thresholded and treatment eligibility increasingly depends on biological evidence that can be measured rather than inferred.
MICSI-PET fits directly into that transition. Automated Centiloid and tau quantification may make PET interpretation more reproducible and easier to compare across centres. That is clinically useful, but precision software sitting on top of inaccessible imaging infrastructure still produces unequal precision medicine.
Executive Summary
Microstructure Imaging announced FDA 510(k) clearance for MICSI-PET, a neurological PET software platform combining MR-guided PET enhancement with automated amyloid and tau quantification.
The platform uses structural MRI to guide PET denoising and super-resolution while maintaining quantitative PET information. It provides automated Centiloid quantification for amyloid PET, CenTauR quantification for tau PET, regional SUVr measurements and z-scores against normative controls.
FDA’s device record identifies MICSI-PET as K261305, with a substantial-equivalence decision dated 11 September 2026.
This is clearance of image-processing and quantification software. It is not approval of a new Alzheimer’s diagnostic test and does not establish that automated quantification independently improves patient outcomes.
Why it matters
- Clinicians: Standardised quantification may improve consistency between readers and centres.
- Diagnostics / pathology: Alzheimer’s imaging is moving from predominantly visual interpretation toward reproducible numerical measures.
- Data / AI leaders: Regulatory clearance places quantitative neuroimaging software more firmly inside routine clinical infrastructure.
- Hospitals / providers: PET access, tracer supply, MRI availability, workflow integration and reimbursement remain the larger implementation constraints.
The Alzheimer’s pathway is increasingly being rebuilt around numbers. Amyloid PET is no longer simply read as positive or negative; disease burden can be expressed on standardised scales. Tau distribution is becoming more clinically relevant. Blood biomarkers are moving earlier into diagnostic pathways. As treatments become tied to biological eligibility, measurement quality begins to influence access itself.
MICSI-PET is part of the infrastructure behind that shift. Automated Centiloid calculation can help express amyloid burden in a standardised form, while CenTauR analysis seeks to do something similar for tau. MR-guided enhancement is intended to improve neurological PET image quality without discarding the quantitative information needed for clinical interpretation. (BioSpace)
Standardisation has a policy consequence. When treatment eligibility or disease staging depends on quantitative thresholds, variation between centres can become an access problem. A patient should not receive a fundamentally different interpretation because one hospital measures pathology differently from another.
The opposite inequality remains larger. Advanced PET imaging is concentrated in specialist centres, and availability, tracer distribution and reimbursement remain uneven. Software can improve the measurement without making the scanner easier to reach.
Precision medicine therefore has two jobs: improve the quality of biological measurement and widen access to the infrastructure capable of producing it. Doing only the first risks creating an extraordinarily precise pathway for a limited group of patients.
